PLAUR and cancer: Collectively, these studies provide a strong rationale for clinical translation of this BLT as adjuvant therapy to supplement standard of care therapies for treating both residual and metastatic, relapsed cancers, such as sarcomas, and potentially other EGFR- and uPAR-expressing cancers.